Accurate Education - The 4 Domain Approach to Chronic Pain - Biomarkers: Ferritin

The 4 Domain Approach to Chronic Pain:

Biomarkers: Ferritin

As a biomarker, ferritin can be complex in its assessment and management of abnormal blood levels. This section is a comprehensive analysis of ferritin thresholds and the diagnostic workup for both low and high values, framed for the 4-D Protocol’s domain profiling. Biomarkers are used in the 4-D protocols to assess the levels of activity of the four domains: systemic inflammation, neuroinflammation, oxidative stress and mitochondrial dysfunction.

Please note this document has been prepared with the assistance of an AI. There may be some errors.

See:

4-D Biomarkers

The 4-Domain Approach to Chronic Pain

See also:

Key to Links:

Grey text – handout
Red text – another page on this website
Blue text – Journal publication

Definitions and Terms Related to Pain

The 4-D Approach to Chronic Pain

Biomarkers: Ferritin

—

Ferritin Thresholds: A Bidirectional Biomarker

Ferritin interpretation in the 4-D Protocol requires understanding that this biomarker provides clinically actionable information in both directions — low values signal iron deficiency that may impair neurotransmitter synthesis and pain modulation, while elevated values signal systemic inflammation, iron overload, or both. Critically, ferritin is an acute-phase reactant, meaning inflammation can increase ferritin by approximately 30–90% depending on the phase of the inflammatory response, masking underlying iron deficiency.[1]

—

Low Ferritin: Thresholds for Identifying Iron Deficiency Relevant to Pain Processing

The appropriate threshold for “low” ferritin depends on the clinical context:

<15 ng/mL (WHO threshold): Highly specific for depleted iron stores but has a sensitivity of only 59% — meaning it misses nearly half of truly iron-deficient patients.[2][3]
<30 ng/mL: The NEJM review identifies this as the most sensitive and specific single test for iron deficiency (sensitivity 92%, specificity 83%). This is the threshold most appropriate for the general chronic pain population without significant comorbid inflammation.[4]
<45 ng/mL: The AGA Clinical Practice Guidelines recommend this threshold based on a systematic review of 55 studies, yielding a sensitivity of 85% and specificity of 92% — the optimal balance for clinical decision-making.[3]
<50 ng/mL: The fibromyalgia-specific threshold. Having a ferritin level below 50 ng/mL conferred a 6.5-fold increased risk of fibromyalgia in a case-control study, even when levels were within the conventional “normal” range. This is particularly relevant for the 4-D Protocol because iron is an essential cofactor for the enzymes that synthesize serotonin, dopamine, and norepinephrine — the neurotransmitters driving the descending modulatory pain pathways.[5][6]
<100 ng/mL: The threshold recommended for identifying iron deficiency in the setting of chronic inflammation (elevated CRP). An NEJM review states that in the context of inflammation, the best predictor of iron-deficiency anemia is a ferritin level <100 µg/L. International guidelines for chronic heart failure and chronic kidney disease also use this threshold when transferrin saturation is <20%. A recent diagnostic algorithm from American Family Physician uses ferritin <100 ng/mL as the iron deficiency threshold when chronic inflammation or chronic disease is present.[4][7][8][9]

For the 4-D Protocol, a practical framework would be:

Ferritin <30 ng/mL → Iron deficiency is highly likely regardless of CRP; initiate repletion
Ferritin 30–50 ng/mL with normal CRP → Probable iron deficiency, particularly relevant in fibromyalgia phenotypes; obtain transferrin saturation to confirm
Ferritin 50–100 ng/mL with elevated CRP (>3 mg/L) → Possible functional iron deficiency masked by inflammation; transferrin saturation <20% confirms iron-restricted erythropoiesis and likely tissue iron depletion[7][4]
Ferritin 50–100 ng/mL with normal CRP → Iron stores likely adequate but borderline; clinical judgment based on symptoms

A novel approach — the ferritin/CRP ratio — has been validated as a simple tool for diagnosing iron deficiency in the presence of inflammation. A ratio of ≤6 (ferritin in µg/L divided by CRP in mg/L) demonstrated an AUC of 0.85–0.92 for identifying iron deficiency across multiple definitions, with an odds ratio of 37.9 in a validation cohort of 795 patients.[10] This could be a practical addition to the 4-D Protocol’s domain profiling when both ferritin and hs-CRP are already being measured.

—

Elevated Ferritin: Thresholds for Identifying Inflammation and Iron Overload

The thresholds for elevated ferritin are sex-dependent:

>200 ng/mL in women, >300 ng/mL in men: The WHO and most international guidelines define these as the thresholds for risk of iron overload. In the HEIRS study (n=99,711), ferritin was elevated above these thresholds in 57% of female and 88% of male C282Y homozygotes.[2][11][12][13]
>500 ng/mL: Warrants more urgent evaluation. A retrospective study of 2,044 patients with ferritin ≥500 ng/mL found that the most common causes were solid organ malignancies (37.1%), infections (23.4%), and hematologic disorders (14.9%).[14]
>1,000 ng/mL: In C282Y homozygotes, this threshold combined with elevated aminotransferases and low platelet count predicts cirrhosis in >80% of patients and warrants liver biopsy.[15][16]

For the 4-D Protocol’s domain profiling, elevated ferritin should be interpreted in conjunction with hs-CRP:

Elevated ferritin + elevated CRP → Most likely reflects the acute-phase response and confirms systemic inflammation domain involvement. Ferritin can be elevated by 30–90% due to inflammation alone. This pattern does not necessarily indicate iron overload but does confirm that the inflammatory domain is active.[1]
Elevated ferritin + normal CRP → Raises concern for true iron overload, metabolic syndrome, liver disease, or hemochromatosis. Requires further workup (see below).
Elevated ferritin + elevated CRP + low transferrin saturation (<20%) → Paradoxical pattern suggesting concurrent iron deficiency and inflammation (functional iron deficiency / iron-restricted erythropoiesis). The inflammation is sequestering iron in reticuloendothelial cells, making it unavailable for erythropoiesis and neurotransmitter synthesis despite apparently adequate stores.[7][8]

—

Diagnostic Workup for Low Ferritin (Confirming and Characterizing Iron Deficiency)

When ferritin is low or borderline-low, the following workup guides correction:

Step 1 — Confirm iron deficiency with iron studies:

Serum iron, TIBC, and transferrin saturation (TSAT): TSAT <16% indicates insufficient iron supply for normal erythropoiesis; <20% is used as the threshold in the presence of inflammation. Normal TSAT is 16–45%.[4][17][18]
CBC with indices: Microcytosis (MCV <80 fL), low mean corpuscular hemoglobin (<27 pg), and low hemoglobin confirm iron-deficiency anemia. However, iron deficiency without anemia is common and clinically relevant — particularly for the 4-D Protocol, where the concern is neurotransmitter synthesis impairment rather than erythropoiesis alone.[5]

Step 2 — If inflammation is present (CRP elevated), consider additional markers:

Soluble transferrin receptor (sTfR): Not an acute-phase reactant, so it remains elevated in true iron deficiency even when ferritin is falsely normalized by inflammation. An sTfR/log ferritin index ≥2 suggests iron deficiency; ≤1 suggests anemia of chronic disease alone.[19][17]
Reticulocyte hemoglobin content (CHr or Ret-He): An early marker of functional iron deficiency, with values <25 pg suggesting iron deficiency.[4]

Step 3 — Identify the cause of iron deficiency:

The AGA guidelines recommend that all adults with iron deficiency anemia undergo bidirectional endoscopy (EGD and colonoscopy) to evaluate for GI blood loss, unless there is an obvious non-GI source (e.g., menorrhagia in premenopausal women).[3]
In premenopausal women with heavy menstrual bleeding and no GI symptoms, a trial of iron repletion with monitoring may be appropriate before endoscopy.
Celiac serologies should be considered, particularly in refractory iron deficiency.

Step 4 — Iron repletion:

Oral iron (ferrous sulfate 325 mg every other day for improved absorption and tolerability) is first-line for most patients.
IV iron (ferric carboxymaltose, iron sucrose, or ferumoxytol) is indicated for intolerance or unsatisfactory response to oral iron, or in the setting of chronic inflammatory conditions where hepcidin-mediated iron sequestration impairs oral absorption.[20][7]
Monitoring: Repeat ferritin and transferrin saturation at 3 and 6 months. Iron replacement should continue until ferritin >100 ng/mL and/or TSAT >30% in at-risk patients, or ferritin >50 ng/mL and TSAT >20% in patients no longer at risk.[21]

—

Diagnostic Workup for Elevated Ferritin (Differentiating Inflammation from Iron Overload)

When ferritin is elevated, the diagnostic approach proceeds stepwise:

Step 1 — Assess for inflammation and common causes:

CRP (or hs-CRP): Already part of the 4-D Protocol panel. If elevated, the ferritin elevation is likely at least partly an acute-phase response.[12][22]
Liver function tests (AST, ALT, GGT): Liver disease (alcoholic, NAFLD, viral hepatitis) is among the most common causes of hyperferritinemia.[22][13]
Fasting glucose/HbA1c, lipid panel, BMI: Metabolic syndrome is a very common cause of elevated ferritin in the general population — more common than hemochromatosis.[12][22]
Alcohol history: Alcohol use is a frequent contributor.

Step 2 — Obtain transferrin saturation:

This is the key branching test. TSAT distinguishes iron overload from non-iron-overload causes of hyperferritinemia.[12][22][16]

TSAT ≥45%: Raises concern for iron overload. Proceed to HFE genetic testing.[15][11][16]
TSAT <45%: Iron overload is unlikely. The hyperferritinemia is most likely due to inflammation, metabolic syndrome, liver disease, or other non-iron-overload causes.[12][22]

Step 3 — If TSAT ≥45%, obtain HFE genotyping:

C282Y homozygosity: Confirms HFE-related hereditary hemochromatosis. A TSAT ≥45% has a sensitivity of 94% in men and 73% in women for detecting C282Y homozygosity.[11]
C282Y/H63D compound heterozygosity: Rarely causes clinically significant iron overload but warrants monitoring.[15]
No HFE mutations with persistent TSAT ≥45%: Consider non-HFE hemochromatosis or secondary iron overload (thalassemia syndromes, myelodysplastic syndrome, sideroblastic anemias, chronic transfusions).[23]

Step 4 — Assess for end-organ iron deposition if hemochromatosis confirmed:

Liver MRI with R2* or T2* quantification: Non-invasive assessment of hepatic iron concentration. This has largely replaced liver biopsy for iron quantification.[24][23]
Liver biopsy: Reserved for patients with ferritin >1,000 ng/mL, elevated aminotransferases, or suspected cirrhosis — primarily to stage fibrosis rather than quantify iron.[15][16]

Step 5 — Management of confirmed iron overload:

Therapeutic phlebotomy: Weekly until ferritin normalizes (<50–100 ng/mL), then maintenance phlebotomy every 2–4 months.[15][12]

—

Integrating Ferritin into the 4-D Protocol’s Domain Profiling

For the 4-D Protocol, ferritin’s value lies in its ability to inform two domains simultaneously:

Ferritin Level	CRP Status	Domain Implication	Clinical Action	Ref
<30 ng/mL	Any	Neuroinflammation (impaired neurotransmitter synthesis)	Confirm with transferrin saturation (TSAT) initiate iron repletion; evaluate cause	[1], [2]
30–50 ng/mL	Normal	Borderline — particularly relevant in FM phenotype (6.5× risk if <50)	Obtain transferrin saturation (TSAT) consider iron repletion if TSAT <20% or FM phenotype	[2], [3]
50–100 ng/mL	Elevated CRP (>3 mg/L)	Possible functional iron deficiency masked by inflammation	Obtain transferrin saturation (TSAT) if <20%, iron deficiency likely despite “normal” ferritin; consider ferritin/CRP ratio ≤6	[1], [4], [5]
>200 (F) >300 (M) ng/mL	Normal	Possible iron overload	Obtain transferrin saturation (TSAT) if ≥45%, proceed to HFE genotyping	[6], [7], [8]
>200 (F) >300 (M) ng/mL	Elevated CRP (>3 mg/L)	Likely acute-phase response confirming systemic inflammation domain	Confirms inflammation domain; transferrin saturation (TSAT) helps exclude concurrent iron overload	[7], [9], [10]
>500 ng/mL	Any	Warrants urgent evaluation regardless of CRP	Full workup including TSAT, HFE genotyping, liver evaluation; consider malignancy, infection, hematologic disorder	[11], [12]

The critical insight for the 4-D Protocol is that conventional “normal” ferritin ranges (20–200 ng/mL in women, 40–300 ng/mL in men) were established for detecting iron-deficiency anemia, not for optimizing neurotransmitter synthesis or pain processing. The fibromyalgia data suggest that ferritin levels well within the “normal” range (<50 ng/mL) may be clinically significant for pain processing, and the inflammation data demonstrate that ferritin levels that appear “normal” may actually mask iron deficiency when CRP is elevated. Both of these nuances are directly relevant to the 4-D Protocol’s goal of identifying modifiable biochemical contributors to pain severity.

References

Adjusting Plasma Ferritin Concentrations to Remove the Effects of Subclinical Inflammation in the Assessment of Iron Deficiency: A Meta-Analysis. Thurnham DI, McCabe LD, Haldar S, et al. The American Journal of Clinical Nutrition. 2010;92(3):546-55. doi:10.3945/ajcn.2010.29284.
Serum or Plasma Ferritin Concentration as an Index of Iron Deficiency and Overload. Garcia-Casal MN, Pasricha SR, Martinez RX, Lopez-Perez L, Peña-Rosas JP. The Cochrane Database of Systematic Reviews. 2021;5:CD011817. doi:10.1002/14651858.CD011817.pub2.
AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Ko CW, Siddique SM, Patel A, et al. Gastroenterology. 2020;159(3):1085-1094. doi:10.1053/j.gastro.2020.06.046.
Iron-Deficiency Anemia. Camaschella C. The New England Journal of Medicine. 2015;372(19):1832-43. doi:10.1056/NEJMra1401038.
Association Between Serum Ferritin Level and Fibromyalgia Syndrome. Ortancil O, Sanli A, Eryuksel R, Basaran A, Ankarali H. European Journal of Clinical Nutrition. 2010;64(3):308-12. doi:10.1038/ejcn.2009.149.
Possible Molecular Mediators Involved and Mechanistic Insight Into Fibromyalgia and Associated Co-Morbidities. Singh L, Kaur A, Bhatti MS, Bhatti R. Neurochemical Research. 2019;44(7):1517-1532. doi:10.1007/s11064-019-02805-5.
Iron Deficiency Screening Is a Key Issue in Chronic Inflammatory Diseases: A Call to Action. Cacoub P, Choukroun G, Cohen-Solal A, et al. Journal of Internal Medicine. 2022;292(4):542-556. doi:10.1111/joim.13503.
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD). Garabed Eknoyan, Norbert Lameire, Wolfgang C. Winkelmayer, et al. Kidney Disease: Improving Global Outcomes.
Iron Deficiency Anemia: Evaluation and Management. Latimer K, Baci G, Layne M. American Family Physician. 2025;112(5):538-545.
Serum Ferritin/C-Reactive Protein Ratio Is a Simple and Effective Biomarker for Diagnosing Iron Deficiency in the Context of Systemic Inflammation. Urbanski G, Chabrun F, Lavigne C, et al. QJM : Monthly Journal of the Association of Physicians. 2024;117(1):9-15. doi:10.1093/qjmed/hcad218.
Hemochromatosis. Olynyk JK, Ramm GA. The New England Journal of Medicine. 2022;387(23):2159-2170. doi:10.1056/NEJMra2119758.
Investigation of a Raised Ferritin-Hereditary Haemochromatosis or Not?. Gurumurthy G, Brown R, Thachil J. QJM : Monthly Journal of the Association of Physicians. 2026;119(4):257-264. doi:10.1093/qjmed/hcaf330.
Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Hepatology (Baltimore, Md.). 2011;54(1):328-43. doi:10.1002/hep.24330.
Unraveling the Differential Diagnosis of Hyperferritinemia: Insights From a Retrospective Study at a Tertiary Care Hospital. Lee LE, Lee SW, Song JJ, Park YB, Jung SM. Postgraduate Medical Journal. 2025;101(1197):612-619. doi:10.1093/postmj/qgae194.
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Kwo PY, Cohen SM, Lim JK. The American Journal of Gastroenterology. 2017;112(1):18-35. doi:10.1038/ajg.2016.517.
ACG Clinical Guideline: Hereditary Hemochromatosis. Kowdley KV, Brown KE, Ahn J, Sundaram V. The American Journal of Gastroenterology. 2019;114(8):1202-1218. doi:10.14309/ajg.0000000000000315.
Iron Deficiency Anaemia. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Lancet (London, England). 2016;387(10021):907-16. doi:10.1016/S0140-6736(15)60865-0.
Anemia in Children With Inflammatory Bowel Disease: A Position Paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. Goyal A, Zheng Y, Albenberg LG, et al. Journal of Pediatric Gastroenterology and Nutrition. 2020;71(4):563-582. doi:10.1097/MPG.0000000000002885.
National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population. Batsuli G, Lewandowska MD, Lim MY, et al. Haemophilia : The Official Journal of the World Federation of Hemophilia. 2026 May-Jun;32(3):646-657. doi:10.1111/hae.70227.
FDA Orange Book. FDA Orange Book.
Defining ferritin clinical decision limits to improve diagnosis and treatment of iron deficiency: A modified Delphi study. Naveed K, Goldberg N, Shore E, et al. International Journal of Laboratory Hematology. 2023;45(3):377-386. doi:10.1111/ijlh.14016.
Investigation and Management of a Raised Serum Ferritin. Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW. British Journal of Haematology. 2018;181(3):331-340. doi:10.1111/bjh.15166.
Iron Overload Disorders. Hsu CC, Senussi NH, Fertrin KY, Kowdley KV. Hepatology Communications. 2022;6(8):1842-1854. doi:10.1002/hep4.2012.
MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes. Viveiros A, Schaefer B, Panzer M, et al. Hepatology (Baltimore, Md.). 2021;74(5):2424-2435. doi:10.1002/hep.31982.
Hemochromatosis. Gary P. Jeffrey, Paul C. Adams. Chapter 36.

Emphasis on Education

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

Should you wish more information regarding any of the subjects listed – or not listed – here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

For more information, please contact Accurate Clinic.

Supplements recommended by Dr. Ehlenberger may be purchased commercially online

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.